Inactive

Update (12/12/22): Please find attached Amendment 5 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 13, 2022. Update (12/09/22): Please find attached Questions ... Update (12/12/22): Please find attached Amendment 5 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 13, 2022. Update (12/09/22): Please find attached Questions and Answers as of December 9, 2022. We've added one additional question and answer. Update (12/02/22): Please find attached Amendment 4 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 12, 2022. Please note that this is intended to be the final extension to the due date for propoals, as it will be difficult to support further extensions while ensuring that the Government is timely prepared for the commercialization of COVID-19 vaccines. Update (12/01/22): Please find attached Amendment 3 to the RFP. This amendment clarifies that CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication. Update (11/30/22): Please find attached Questions and Answers as of November 30, 2022. With the closing of the question and answer period on November 29, 2022, this is expected to be the final version of the questions and answers document. Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022. Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022. Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022. Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022. Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022. The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older. Item Description and Quantities COVID-19 Vaccine – Adult (age 19 years and older) Maximum ordering quantity: Up to 30 million doses Minimum ordering quantity: 100 doses Min. Order Size: 100 Doses Fed. Excise Tax: $0.75 per dose Ordering period: One year from date of award The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds. Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award. For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC. Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483. Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice. This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed. Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.